<DOC>
	<DOC>NCT03052322</DOC>
	<brief_summary>The purpose of this study is to compare the efficacy, safety and immunogenicity of MSB11022 and HumiraÂ® in adult subjects with rheumatoid arthritis.</brief_summary>
	<brief_title>MSB11022 in Moderate to Severe Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of rheumatoid arthritis based on 2010 ACR/EULAR criteria At least 6 tender (of 68 assessed) and 6 swollen (of 66 assessed) joints at screening and baseline Must have received methotrexate for at least 12 weeks and been on a stable dose for at least 4 weeks prior to the first study dose Evidence of untreated or inadequately treated latent or active Tuberculosis Evidence of uncontrolled, clinically significant diseases Any second diseasemodifying antirheumatic drugs must be washed out prior to the first study dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>